Systemic therapy of kidney cancer: Tyrosine kinase inhibitors antiagiogenesis or IL-2?

Future Oncology

Volumn 5, Issue 6, 2009, Pages 871-888

  Kirkali, Ziya ^a   Tüzel, Emre ^b  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b AFYON KOCATEPE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Angiogenesis inhibitors; Bevacizumab; Interleukin 2; Mammalian target of rapamycin; Multikinase inhibitors; Renal cell carcinoma; Sorafenib; Sunitinib; Targeted therapy; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; HYPOXIA INDUCIBLE FACTOR; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VON HIPPEL LINDAU PROTEIN;

CANCER SURVIVAL; CLINICAL TRIAL; DRUG MEGADOSE; GENE MUTATION; HIGH RISK PATIENT; HUMAN; KIDNEY CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG DELIVERY SYSTEMS; HUMANS; INTERLEUKIN-2; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 70349209358     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.51     Document Type: Review

References (94)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108 (2005).
2. Gleave ME, Elhilali M, Fradet Y et al.: Interferon γ-1b compared with placebo in metastatic renal cell carcinoma. N. Engl. J. Med. 338, 1265-1271 (1998).
3. Störkel S, Eble JN, Adlakha K et al.: Classification of renal cell carcinoma: Workgroup no. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC), Cancer 80, 987-989 (1997).
4. Atkins MB, Regan M, McDermott D: Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin. Cancer Res. 10(18 Part 2), S6342-S6346 (2004).
5. Hutson TE, Figlin RA: Renal cell cancer. Cancer J. 13, 282-286
6. Kim WY, Kaelin WG: Molecular pathways in renal cell carcinoma - rationale for targeted treatment. Semin. Oncol. 33, 588-595 (2006).
7. Gnarra JR, Tory K, Weng Y et al.: Mutations of the VHL tumor suppressor gene in renal carcinoma. Nat. Genet. 7(1), 85-90 (1994).
8. Blakenship C, Naglich JG, Whalet et al.: Alternate choice of initiation codon procedures a biologically active product of the von Hippel Lindau gene with tumor suppressor activity. Oncogene 18, 1529-1535 (1999).
9. Kaelin WG: Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer 2, 673-682 (2002).
10. Semenza GL: HIF-1 and mechanisms of hypoxia sensing. Curr. Opin. Cell Biol. 13, 167-171 (2001).
11. 2 regulated prolyl hydroxylation. Science 292, 468-472 (2001).
12. Semenza GL: Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3, 721-732 (2003).
13. Harris AL: Hypoxia - a key regulatory factor in tumor growth. Nat. Rev. Cancer 2, 38-47 (2002).
14. Caldwell MC, Hough C, Furer S et al.: Serial analysis of gene expression in renal carcinoma cells reveals VHL-dependent sensitivity to TNF-α cytotoxicity. Oncogene 21, 929-936 (2002).
15. Sakamato S, Ryan AJ, Kyprianu N: Targeting vasculature in Urologic tumors: mechanistic and therapeutic significance. J. Cell. Biochem. 103, 691-708 (2008).
16. Folkman J: Clinical applications of research on angiogenesis. N. Engl. J. Med. 333, 1757-1763 (1995).
17. de Vries C, Escobedo JS, Ueno H, Houck K, Ferrara N, Williams LT: The fms-like tyrosine kinase a receptor for vascular endothelial growth factor. Science 255, 989-991 (1992).
18. Millauer B, Wizigmann-Voos S, Schnurch H et al.: High affinity VEGF binding and developmental expression suggests flk-I as a major regulator of vasculogenesis and angiogenesis. Cell 72, 835-846 (1993).
19. Cho D, Signoretti S, Regan M et al.: The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin. Cancer Res. 13, S758-S763 (2007).
20. Le Tourneau C, Faivre S, Raymond E: mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work? Br. J. Cancer 99, 1197-1203 (2008).
21. Faivre S, Kraeme G, Ramond E: Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 5, 671-688 (2006).
22. Brenner W, Farber G, Herget T, Lehr HA, Heggstler JG, Thuroff W: Loss of tumor suppressor protein PTEN during renal angiogenesis. Int. J. Cancer 99, 53-57 (2002).
23. Hamada K, Sasaki T, Koni PA et al.: The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev. 19, 2054-2065 (2005).
24. Gaba M, von Breitenbuch P, Steinbauer M et al.: Rapamycin inhibits primary and metastatic tumor growth by anti-angiogenesis involvement of vascular endothelial growth factor. Nat. Med. 8, 128-135 (2002).
25. Arsham AM, Plas DR, Thompson CB, Simon MC: Phosphatidylinositol 3-kinase/ Akt signaling is neither required for hypoxic stabilization of HIF-1 α nor sufficient for HIF-1 dependent target gene transcription. J. Biol. Chem. 277(17), 15162-15170 (2002).
26. Chow LQ, Eckhardt SG: Sunitinib from rational design to clinical efficacy. J. Clin. Oncol. 25, 884-896 (2007).
27. Faivre S, Delbaldo, Vera K et al.: Safety, pharmacokinetic and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol. 24, 25-25 (2007).
28. Motzer RJ, Michaelson MD, Redman BG et al.: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 16-24 (2006).
29. Motzer RJ, Rini BI, Bukowski RM et al.: Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295, 2516-2524 (2006).
30. Motzer RJ, Mazumdar M, Bacik J et al.: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17, 2530-2540 (1999).
31. Motzer RJ, Michaelson MD, Rosenberg J et al.: Sunitinib efficacy against advanced renal cell carcinoma. J. Urol. 178, 1883-1887 (2007).
32. Motzer RJ, Hutson TE, Tomczak P et al.: Sunitinib versus interferon α in metastatic renal cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007).
33. Figlin TA, Hutson TE, Tomczak P et al.: Overall survival with sunitinib versus interferon (IFN) α as first line treatment of metastatic renal-cell carcinoma (mRCC). J. Clin. Oncol. 26(Suppl.), S256 (2008) (Abstract 5024).
34. Gore M, Szczylik C, Porta C et al.: Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of safety and efficacy in an expanded access trial with subpopulation analysis. Eur. J. Cancer 5 (Suppl.), 299 (2007) (Abstract 4503).
35. Wilhelm SM, Carter C, Tang L et al.: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109 (2004).
36. Ratain MJ, Eisen T, Stadler WM et al.: Phase II placebo controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 2505-2512 (2006).
37. Escudier B, Szcylik C, Demkov T et al.: Randomized Phase II trial of the multikinase inhibitor sorafenib versus interferon (IFN) in treatment naïve patients with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 24(Suppl. 18), 4501 (2006).
38. Escudier B, Eisen T, Stadler WM et al.; TARGET Study Group: sorafenib in advanced clear cell renal carcinoma. N. Engl. J. Med. 356, 125-134 (2007).
39. Bukowski RM, Eisen T, Szcylik C et al.: Final results of the randomized Phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. J. Clin. Oncol. 25(Suppl.), 5023 (2007).
40. Beck J, Procopio E, Verzoni S et al.: Large open label non-comparative clinical experience trial of the multi-targeted kinase inhibitor salraftnib in-European pati.ents with advanced RCC. J. Clin. Oncol. 26(Suppl.) (2008) (Abstract 1621).
41. Shepard DR, Rini BI, Garcia A et al.: A multicenter prospective trial of sorafenib in patients with metastatic clear cell renal cell carcinoma refractory to prior sunitinib or bevacizumab. J. Clin. Oncol. 26(Suppl.) (2008) (Abstract 5123).
42. Szczylik C, Demkow T, Staehler M et al.: Randomized Phase II trial of first line treatment with sorafenib versus IFN in patients with advanced renal cell carcinoma: final results. J. Clin. Oncol. 25 (Suppl.) (2007) (Abstract 5025).
43. Atkins MB, Hidalgo M, Stadler WM et al.: Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 22, 909-918 (2004).
44. Hudes G, Carducci M, Tomczak P et al.: Temsirolimus, interferon α or both for advanced renal cell carcinoma. N. Engl. J. Med. 356, 2271-2281 (2007).
45. Motzer RJ, Michaelson MD, Hutson TE: Sunitinib versus interferon-α as first line treatment of metastatic renal cell carcinoma: updated efficacy and safety results and further analysis of prognostic factors. Eur. J. Cancer 5(Suppl.) (2007) (Abstract 301).
46. Jac J, Giessinger S, Khan M et al.: A Phase II trial of RAD001 in patients with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 25(Suppl.) (2007) (Abstract 5107).
47. Motzer RJ, Escudier B, Ouard S et al.: Efficacy of everolimus in advanced renal cell carcinoma: a double blind, randomized, placebo-controlled Phase II trial. Lancet 372, 449-456 (2008).
48. Yang JC, Haworth L, Sherry RM et al.: A randomized trial of bevacizumab an anti-vascular endothelial growth factor antibody for metastatic renal cancer. N. Engl. J. Med. 349, 427-434 (2003).
49. Escudier B, Pluzanska A, Koralewski P et al.: Bevacizumab plusIFN α-2a for treatment of metastatic renal cell carcinoma: a randomised, double blind Phase III trial. Lancet 370, 2103-2111 (2007).
50. Rini BI, Halabi S, Rosenberg JE et al.: Bevacizumab plus interferon α compared with interferon α monotherapy in patients with metastatic renal cell carcinoma: CALGB. J. Clin. Oncol. 26, 5422-5428 (2008).
51. Choueiri TK, Plantade A, Elson P et al.: Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J. Clin. Oncol. 26, 171-131 (2008).
52. Dutcher J, de Souza P, McDermott DR et al.: Effect of remsirolimus versus interferon-α on survival of patients with advanced renal cell carcinoma of different rumor histologies. Med. Oncol. 26(2), 202-209 (2009).
53. Schrader AJ, Olbert PJ, Hegele A, Varga Z, Hofmann R: Metastatic non-clear cell renal cell carcinoma: current therapeutic options. BJU Int. 101, 1343-1345 (2008).
54. Mian BM, Bhadkamkar N, Slaton JW et al.: Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J. Urol. 167, 65-70 (2002).
55. Beck J, Bajetta E, Escudier B et al.: Large open label, non-comparative, Phase III study of the multi-targeied kinase inhibitor sorafenib in European patients with advanced renal cell carcinoma. Eur. J. Cancer 5 (Suppl.), 300 (2007) (Abstract 4506).
56. Golshayan AR, George S, Heng DY et al.: Metastatic renal cell carcinoma (mRCC) patients with sarcomatoid features treated with VEGF-targeted therapy. J. Clin. Oncol. 26(Suppl.) (2008) (Abstract 5102).
57. Whorf JD, Hainsworth DR, Spigel DA et al.: Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC). J. Clin. Oncol. 26(Suppl.) (2008) (Abstract 5010).
58. Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A: Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J. Clin. Oncol. 23, 7889-7896 (2005).
59. Bukowski RM, Kabbinavar FF, Figlin RA et al.: Randomized Phase II study of erlotinib combined with bevacizumab compared with bevaczumab alone in metastatic renal cell cancer. J. Clin. Oncol. 29, 4536-4541 (2007).
60. George-DJ, Michaelson MD, Rosenberg JE et al.: Phase II trial of sunitinib in bevacizumab refractory metastatic renal cell cancer: updated results and analysis of circulating biomarkers. J. Clin. Oncol. 25(Suppl.) (2007) (Abstract 5035).
61. Rixe O, Bukowski RM, Michaelson MD et al.: Axitinib treatment in patients with cytokine refractory metastatic renal cell cancer: a Phase II study. Lancet Oncol. 8(11), 975-984 (2007).
62. Rini B, Wilding GT, Hudes G et al.: Axitinib (AG-013736; AG) in patients with metastatic renal cell cancer refractory to sorafenib. J. Clin. Oncol. 25(18S), 5032 (2007).
63. Sonpavde G, Hutson TE: Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr. Oncol. Rep. 9(2), 115-119 (2007).
64. Hutson TE, Davis ID, Machiels JP et al.: Pazopanib (GW786034) is active in metastatic renal cell carcinoma. Interim results of a Phase II randomized discontinuation trial. J. Clin. Oncol. 25(Suppl.), 5031 (2007).
65. Bhargava P, Esteves O, Liparov ON et al.: Activity and safety of AV-951, a potent and selective VEGFR1, 2 and 3 kinase inhibitor, in patients with renal cell carcinoma: interim results of a Phase II randomized discontinuation trial. Presented at: ASCO Genitourinary Cancers Symposium. Orlando, FL, USA. 26-28 February 2009 (Abstract 283).
66. Bellmunt J: The oncolgist's view: targeted therapies in advanced renal cell carcinoma. Eur. Urol. 7(Suppl. 2), 55-62 (2008).
67. Hutson TE, Figlin RA, Kuhn JG, Motzer RJ: Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 13, 1084-1096 (2008).
68. Rini BI, Choueiri TK, Elson P et al.: Sunitinib induced macrocytosis in patients with metastatic renal cell carcinoma. Cancer 113, 1309-1314 (2008).
69. Flanigan RC, Salmon SE, Blumenstein BA et al.: Nephrectomy followed by interferon α-2b compared with interferon α-2b alone for metastatic renal cell cancer. N. Engl. J. Med. 345, 1655-1659 (2001).
70. Nanus DM, Pfeffer LM, Bander NH, Bahri S, Albino AP: Antiproliferative and antitumor effects of α interferon in renal cell carcinomas: correlation with the expression of a kidney associated differentiation glycoprotein. Cancer Res. 50, 4190-4194 (1990).
71. Coppin C, Porzsolt F, Awa A et al.: Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev. 1, CD01425 (2005).
72. Rosenberg SA: Progress in human tumor immunology and immunotherapy. Nature 411, 380-384 (2001).
73. Fehniger TA, Cooper MA, Caliguiri MA: Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev. 13, 169-183 (2002).
74. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high dose recombinant interleukin therapy. J. Clin. Oncol. 13, 688-696 (1995).
75. Fisher RI, Rosenberg SA, Fyfe G: Long term survival update for high dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J. Sci. Am. 6(Suppl. 1), S55-S57 (2000).
76. McDermott DF, Regan M, Clack JI et al.: Randomized Phase III trial of high dose interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 23, 133-141 (2005).
77. Yang JC, Sherry RM, Steinberg SM et al.: Randomized study of high dose and low dose interleukin-2 in patients with metastatic renal cell cancer. J. Clin. Oncol. 16, 3127-3132 (2003).
78. Schmidinger M, Hejna M, Zielinski CC: Aldesleukin in advanced renal cell carcinoma. Expert Rev. Anticancer Ther. 4, 957-980 (2004).
79. Atzpodien J, Kirchner H, Jonas U et al.: Interleukin-2 and interferon α-2a based immunotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal, Carcinoma Chemoimmunotherapy Group (DGCIN). J. Clin. Oncol. 22, 1188-1194 (2004).
80. Boccardo, F, Rubagotti A, Canabbia L et al.: Interleukin-2, interferon-a and interleukin-2 plus interferon-a in renal cell carcinoma. A randomized Phase II trial. Tumori 84, 534-539 (1998).
81. Henriksson R, Nilsson S, Colleen S et al.: Survival in renal cell carcinoma: a randomized evaluation of tamoxifen vs interleukin-2, α-interferon and tamoxifen. Br. J. Cancer 77, 1311-1317 (1998).
82. Negrier S, Escudier B, Lasset C et al.: Recombinant human interleukin-2, recombinant human interferon α-2a, or both in metastatic renal cell carcinoma. Grouppe François d'Immunotherapie. N. Engl. J. Med. 338, 1272-1278 (1998).
83. Klatte T, de Martino M, Shuch B et al.: Long term outcome of interleukin-2 based immunotherapy for the treatment of metastatic renal cell carcinoma. J. Clin. Oncol. 26(Suppl.) (2008) (Abstract 5119).
84. Bui MHT, Seligson D, Han K et al.: Carbonic anhyrase IX is an independent predictor of survival in advanced renal cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res. 9, 802-811 (2003).
85. Atkins M, Regan M, McDermott D et al.: Carbonic anhydrase IX expression predicts outcome of interleukin-2 therapy for renal cancer. Clin. Cancer Res. 11, 3714-3721 (2005).
86. Eisenhauer EA, Therasse P, Bogaerts J et al.: New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228-247 (2009).
87. Figlin RA, Hutson TE, Tomczak P et al.: Overall survival with sunitinib versus interferon (IFN) - α as first line treatment of metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 26(Suppl.) (2008) (Abstract 5024).
88. Ljunberg B, Hanbury DC, Kuczyk MA et al.: Renal cell carcinoma guideline. Eur. Urol. 51, 1502-1510 (2007).
89. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 20, 289-296 (2002).
90. Szczylik C, Demkov T, Staehler M, Rolland F, Negrier S. Randomized Phase II trial of first line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J. Clin. Oncol. 25(Suppl.) (2007) (Abstract 5025).
91. Mills EJ, Rachlis B. O'Regan C, Thabane L, Perri D: Metastatic renal cell cancer treatments: an indirect meta-analysis. BMC Cancer 9, 34-42 (2009).
92. Thomas AA, Rini BI, Lane BR et al.: Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J. Urol. 181, 518-523 (2009)
93. Jonasch E, Tannir N: Adjuvant and neoadjuvant therapy in renal cell carcinoma. Cancer J. 14, 315-319 (2008).
94. Kirkali Z: Editorial Comment on: prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. Eur Urol. 55(2), 460 (2009).